RAS genes are the most commonly mutated oncogenes in human cancers. Despite tremendous efforts over the past several decades, however, RAS-specific inhibitors remain elusive. Thus, targeting RAS remains a highly sought-after goal of cancer research. Previously, we have reported a new approach to inhibit RAS-dependent signaling and transformation in vitro by targeting the α4-α5 dimerization interface with a novel RAS-specific monobody termed NS1. Expression of NS1 inhibits oncogenic K-RAS and H-RAS signaling and transformation in vitro. Here, we evaluated the efficacy of targeting RAS dimerization as an approach to inhibit tumor formation in vivo. Using a doxycycline (DOX)-regulated NS1 expression system, we demonstrate that DOX-induced NS1 inhibited oncogenic K-RAS-driven tumor growth in vivo. Furthermore, we observed context-specific effects of NS1 on RAS-mediated signaling in 2D vs 3D growth conditions. Finally, our results highlight the potential therapeutic efficacy of targeting the α4-α5 dimerization interface as an approach to inhibit RAS-driven tumors in vivo.
Introduction
RAS proteins are binary molecular switches that cycle between an inactive GDP-bound state and an active GTPbound state [1] . Normally, RAS regulates a variety of physiological processes including growth, proliferation, survival, and motility [2, 3] . Following growth factor stimulation of cells, guanine nucleotide exchange factors (GEFs) promote the release of GDP from RAS, resulting in the subsequent binding of GTP and engagement of effector proteins. Activated RAS-GTP is converted back to its inactive GDP-bound state through the intrinsic GTPase activity of the protein, which is enhanced by GTPase-accelerating proteins (GAPs) [4] [5] [6] . However, oncogenic activation of RAS occurs through point mutations at various hotspots, predominantly at codons 12, 13, and 61. These mutations impair the intrinsic GTPase activity of RAS and interfere with GAP binding, thereby resulting in constitutive engagement of effector pathways [7] . Mutations in one of the three RAS genes (H-RAS, K-RAS, and N-RAS) occur in nearly 30% of human tumors, with K-RAS mutations accounting for nearly 85% of these mutants [1, 7] . The importance of RAS in cancer is supported by numerous lines of evidence, demonstrating the role of mutant RAS in driving tumor development as well as the dependence of RAS mutant tumors on the continued presence of oncogenic RAS for tumor maintenance. Thus, much effort has been devoted to the development of therapeutic approaches to inhibit RAS in vivo.
Despite the success of ATP-competitive inhibitors at blocking kinases, targeting guanine nucleotide binding by RAS proteins has been largely unsuccessful due, in part, to the picomolar affinity of RAS for GTP/GDP. Subsequent efforts have been focused on interfering with the membrane localization of RAS, which is required for its biological activity. Farnesyltransferases mediate the post-translational attachment of farnesyl lipids to the C-terminal CaaX motif, which is essential for membrane association of RAS.
Although farnesyltransferase inhibitors showed significant efficacy in reducing the growth of H-RAS-driven tumors in preclinical studies, these inhibitors have been ineffective clinically due to the fact that most RAS mutant solid tumors possess either mutant K-RAS or N-RAS. Unlike H-RAS, these RAS proteins evade the inhibitory effect of farnesyltransferase inhibitors due to alternative lipidation mechanisms [8, 9] . Therefore, new therapeutic approaches to inhibit RAS are needed.
Accumulating evidence reveals a previously underappreciated aspect of RAS biology, namely formation of RAS dimers and higher order nanoclusters [10] [11] [12] [13] . Despite the inability of RAS to form dimers in solution or on artificial membrane structures [14, 15] , significant evidence points to a role for RAS dimerization in the activation of downstream pathways [16] . The lack of RAS dimerization in vitro vs in cells may stem from the involvement of additional cellular factors that assist in the dimerization of RAS at the plasma membrane. However, the lack of an available means to specifically disrupt these RAS dimers/ nanoclusters has prevented the analysis of their importance in RAS signaling.
We isolated a high-affinity synthetic binding protein (monobody) called NS1 that selectively binds to H-RAS and K-RAS with high affinity [17] . Biochemical and structural analyses revealed that NS1 binds to the α4-α5 interface of RAS, disrupting RAS dimerization and nanoclustering [17, 18] . NS1 potently inhibited oncogenic RASmediated RAF dimerization and activation, revealing for the first time the importance of RAS self-association with the α4-α5 interface as a requisite step in the activation of downstream effectors such as RAF [17] . Although the expression of NS1 in cells potently inhibited H/K-RASmediated signaling and transformation in vitro, the question remains whether targeting the α4-α5 interface represents a viable approach to inhibit oncogenic RAS in vivo. Here, we evaluated the efficacy of using a chemically regulated, genetically encoded NS1 construct to interfere with RAS dimerization/nanoclustering as a means of inhibiting RASdriven tumor development in vivo. Our findings indicate that targeting the α4-α5 interface represents a potential approach to block RAS-driven tumors in vivo.
Results

Inducible expression of NS1 selectively inhibits the signaling and proliferation of K-RAS mutant human tumor cells
To determine whether targeting the α4-α5 interface was sufficient to block RAS-driven tumor formation in vivo, we established a doxycycline (DOX)-regulated expression system to generate NS1-inducible subclones of various human tumor cell lines harboring mutations in either K-RAS or N-RAS. Our prior results demonstrated the specificity of NS1 in binding and inhibiting K-RAS and H-RAS in vitro, but not of N-RAS due to sequence-specific differences in these RAS isoforms [17] . Thus, we anticipated that NS1 would inhibit K-RAS, but not N-RAS, mutant human tumor lines. We isolated stable subclones of CFPAC-1 pancreatic cancer cells [K-RAS(G12V) mutant], HEC1A endometrial cancer cells [K-RAS(G12D) mutant], H1792 lung adenocarcinoma cells [K-RAS(G12C) mutant] and H1299 nonsmall cell lung carcinoma cells [N-RAS(Q61K) mutant]. The effects of NS1 expression on RAS signaling varied between tumor lines ( Fig. 1 ). DOX-induced CFP-NS1 expression decreased pERK levels in both CFPAC-1 and H1792 lines ( Fig. 1a and Supplementary Figure 1B ). In addition, the transient expression of CFP-NS1 reduced pERK levels in PANC-1 pancreatic cancer cells [K-RAS (G12D) mutant] and H1915 non-small cell lung carcinoma cells [H-RAS(Q61L) mutant] (Supplementary Figure 3A and B). However, there was no change in pERK levels in HEC1A ( Fig. 1b) , consistent with prior studies demonstrating that the deletion of mutant K-RAS attenuated the tumorigenic properties of HEC1A independent of the effects on the Raf/MEK/ERK pathway [19, 20] . As anticipated, NS1 did not affect ERK activation in H1299 cells [N-RAS(Q61K) mutant] or SK-N-AS neuroblastoma cells [N-RAS(Q61K) mutant], demonstrating that the isotype specificity of NS1 is maintained in tumor cells ( Fig. 1c and Supplementary Figure 3C ). In contrast to the effects on pERK, NS1 expression increased pAKT levels in CFPAC-1, H1792, and HEC1A cells ( Fig. 1a, b and Supplementary Figure 1C ). While the effects of NS1 on RAS signaling were cell-type dependent, NS1 expression reduced the proliferation of K-RAS mutant, but not N-RAS mutant, tumor cells ( Fig. 1d-f 
and Supplementary Figures 1C and D).
To further validate that the effects of NS1 were mediated specifically by NS1, we generated DOX-inducible CFPexpressing versions of various mutant K-RAS mutant cells. Selective expression of CFP was observed in all lines by DOX induction; however, DOX induction of CFP did not affect RAS signaling ( Supplementary Figure 4) . These results demonstrate that the inhibition of ERK is specifically due to NS1 expression and not due to CFP or non-specific effects of DOX.
Targeting the RAS α4-α5 interface inhibits anchorage-independent growth of K-RAS mutant tumor cells Next we evaluated the ability of NS1 to inhibit the growth of tumor cells in 3D culture. Consistent with the effects of NS1 on RAS-mediated cell proliferation in 2D culture, NS1 inhibited the anchorage-independent growth of K-RAS mutant tumor lines (CFPAC-1 and HEC1A) in soft agar but did not affect the growth of N-RAS mutant cells (H1299) ( Fig. 2) . Similar results were observed with various HEC1A-derived isogenic cell lines (Supplementary Figure  2 ). These results demonstrate the efficacy of NS1 at specifically inhibiting the 3D growth of K-RAS, but not N-RAS, mutant tumor cells.
Inhibiting RAS dimerization blocks the growth of K-RAS-driven tumors in vivo
Given the ability of NS1 to inhibit the in vitro growth of K-RAS mutant cells in both 2D and 3D, we next assessed the efficacy of targeting the α4-α5 interface as an approach to inhibit RAS-driven tumorigenesis in vivo. RAS mutant tumor cells stably transfected with DOX-inducible NS1 were injected subcutaneously (s.c.) into athymic nude mice. Two days following injection, mice were randomly segregated into DOX-treated (+ DOX) or untreated groups (-DOX). DOX-induced expression of NS1 significantly inhibited the growth of both CFPAC-1 and HEC1A tumors but did not affect the growth of N-RAS mutant H1299 tumors (Figs. 3a, b and 4). Analysis of tumor lysates revealed that NS1 was expressed in all DOX-treated groups, but attenuated ERK activation only in K-RAS mutant tumors (CFPAC-1 and HEC1A) and not in N-RAS mutant tumors (H1299) (Figs. 3c, d and 5).
Next, we evaluated the efficacy of NS1 at reducing tumor burden in established tumors. CFPAC-1 or HEC1A cells were injected s.c. into athymic nude mice. Once tumors attained an average size of 50-70 mm 3 (day 9), mice were randomized and divided into no-DOX (-DOX) and DOXtreated (+ DOX, day 9) cohorts. NS1 induction slowed down tumor progression in DOX-treated mice, and this effect was more pronounced in HEC1A vs CFPAC-1 cells ( Fig. 4 ). . Western blot analysis of tumor lysates confirmed the selective expression of NS1 in tumors from DOX-treated mice for both CFPAC-1 and HEC1A tumors. In contrast to the results with HEC1A cells grown in 2D conditions, NS1 expression at both initial and later time points of tumor growth resulted in decreased pERK levels in tumors. However, the effects of NS1 on AKT activation were less dramatic than those on ERK, with only a slight decrease in pAKT levels upon induction of NS1 expression at either time point ( Fig. 5a ). For CFPAC-1-derived tumors, the effects of NS1 on ERK-MAPK signaling arm were consistent with cell culture data. However, the effects on PI3K-AKT signaling in 3D differed. Although NS1 appeared to augment AKT activity under 2D growth conditions, we observed a significant decrease in pAKT levels in CFPAC-1 tumors in vivo upon NS1 induction (compare Figs. 1a and 5b).
RAS inhibition results in context-dependent effects on signaling pathways
Inhibiting RAS dimerization induces caspase-3 activation and apoptosis in K-RAS mutant tumors
Next, we examined whether the inhibition of RAS dimerization altered the survival of tumor cells in vivo. Caspase-3 was used as an indicator of apoptosis induction since different upstream pathways leading to apoptosis depend on caspase-3 induction for the final apoptotic execution [21] . NS1 induction resulted in the activation of caspase-3 in K-RAS mutant (CFPAC-1 and HEC1A), but not N-RAS mutant (H1299), tumors ( Fig. 6) . Surprisingly, the level of caspase-3 activation was higher in tumors treated with DOX at later times (compare day-2 vs day-9 treatment cohorts) for both HEC1A-and CFPAC-1-derived tumors (Fig. 6 ).
Discussion
Given the prominence of activating RAS mutations in human cancers and the importance of mutant RAS as a driver of tumorigenesis, there has been a great deal of interest in therapeutically targeting RAS [1, 7] . Although initial efforts to therapeutically inhibit RAS by blocking the C-terminal farnesylation of the protein have been disappointing, recent results with mutation-specific inhibitors have provided significant hope for the possibility of pharmacologically inhibiting RAS [22] . Shokat and colleagues utilized a novel tethering approach to selectively target the thiol group of RAS(G12C) mutant resulting in the isolation of several inhibitor compounds that lock RAS into the GDP-bound conformation while also disrupting RAS interaction with Sos. Thus, these compounds result in the accumulation of RAS in the inactive, GDP-bound state. Subsequent improvements to the chemistry of these lead compounds have resulted in the most recent interaction, ARS-1620, which demonstrates selective inhibition of K-RAS(G12C) mutant tumor models in vivo [23] . Although these results provide significant hope for the development of an effective RAS therapeutic, such compounds will be limited to treating G12C mutant tumors. Thus, the identification of more broadly efficacious inhibitors that target mutant RAS proteins remains an unmet need. Selective expression of NS1 decreased the proliferation of K-RAS-but not N-RAS-driven tumor cells, consistent with our prior analysis of NS1 specificity. These effects were corroborated by the potency of NS1 in abrogating anchorage-independent growth of K-RAS, but not N-RAS, mutant tumor cells in soft agar assays. However, the impact Fig. 2 Targeting the α4-α5 interface reduces the anchorageindependent growth of K-RAS mutant tumor cells. Various K-RAS and N-RAS mutant lines from Fig. 1 were plated in soft agar and then treated with ( + ) or without (-) DOX. Media was replenished every 2 days and colony formation was analyzed after 21 days. The graphs
show the average colony number per well from three wells ± SD. Colonies were counted using NIH ImageJ software. Images are representative wells from each assay. a CFPAC-1, pancreatic tumor cells; b HEC1A, endometrial tumor cells; c H1299, lung cancer line of NS1 on RAS signaling in 2D-adherent tissue culture conditions was varied. NS1 decreased ERK activity in CFPAC-1 pancreatic and H1792 lung cancer cells, each of which harbors a mutant K-RAS allele (G12V and G12C, respectively), further demonstrating the importance of α4-α5 dimerization in oncogenic RAS signaling. In contrast, NS1 did not affect ERK activity in the HEC1A cells grown in culture despite the presence of oncogenic K-RAS(G12D) mutant. Similar results were obtained with isogenic derivatives of HEC1A cells in which either the wild type or mutant K-RAS allele was deleted. These results are consistent with previous reports [19, 20] demonstrating that ERK activity in HEC1A cells is unaffected by the deletion (or inhibition) of K-RAS, at least under 2D growth conditions.
The effects of NS1 on K-RAS signaling, however, were highly dependent on context. Under 2D-adherent culture conditions, NS1 increased AKT activity in K-RAS mutant tumor lines (HEC1A, CFPAC-1, and H1792) despite inhibiting ERK activation in CFPAC-1 and H1792 cells and reducing the growth of all three lines in culture. A paradoxical observation of elevated pAKT levels on loss of K-RAS has been recently reported by others [24] . These results were initially surprising given our previous findings that NS1 expression reduced the activation of ERK and AKT by both oncogenic H-RAS and K-RAS when transiently co-expressed in cells [17] . Furthermore, NS1 expression in HEC1A cells did not affect ERK activation in vitro despite significantly inhibiting the proliferation of these cells. However, when cells were grown under 3D conditions, different results were observed. NS1 expression in HEC1A tumors reduced pERK levels regardless of whether NS1 was induced at the time of cell inoculation or once tumors formed. Other groups have reported contextdependent effects of K-RAS inhibition as well. Vartanian et al. observed varied dependence on mutant K-RAS in cells grown in culture vs anchorage-independent conditions, with cells exhibiting the strongest dependence on mutant K-RAS under the later conditions [20] . Treatment of K-RAS(G12C) mutant cells with ARS-1620 resulted in consistent growth Fig. 1 . The asterisks in (d) denote samples that appear to have been switched between treated and control groups. e, f Quantification of pERK activation in tumor lysates from (c, d) was done using NIH Image as previously described [17] and presented as relative pERK activation compared to untreated samples. Error bars represent SEM P values are indicated above the graphs and were calculated using Student's t test inhibition of cells grown as spheroids but had more varied effects on cells grown under 2D-adherent conditions [23] . Despite these varied effects on signaling under different conditions, targeting the α4-α5 dimerization interface nonetheless inhibited the growth of K-RAS mutant tumor cells in vivo. Further, targeting the α4-α5 interface of RAS induced apoptosis in K-RAS, but not N-RAS, mutant tumors. The ability of NS1 to inhibit K-RAS, but not N-RAS, mutant tumors further illustrates the specificity of NS1 and the lack of "off-target" effects. While targeting the α4-α5 dimerization interface with NS1 inhibits the establishment of K-RAS mutant tumors, inhibiting RAS dimerization may also be efficacious at reducing tumor growth once tumors are established. Expression of NS1 reduced HEC1A tumor progression in vivo. However, established CFPAC-1 tumors appeared more refractory to the inhibitory effects of NS1. The lack of tumor regression may stem from incomplete or insufficient NS1 expression in a subpopulation of cells within the tumor. Alternatively, it is possible that a subpopulation of tumor cells has become resistant to the inhibitory effects of NS1, resulting in the outgrowth of a resistant population. Indeed, analysis of cell lines derived from individual tumors expressing NS1 suggests that some tumors may have developed a resistance to the effects of NS1 (unpublished observations). Defining the mechanism of such resistance may reveal alternative mechanisms through which tumor cells can adapt to RAS inhibition and thus affect the therapeutic efficacy of RAS inhibitors in the clinic.
The importance of the α4-α5 interface in K-RAS tumorigenesis is further supported by the recent work of Ambrogio et al. [25] . They demonstrate that mutations in the α4-α5 region that disrupt dimerization reduce the oncogenic activity of K-RAS. Interestingly, such dimerization-disrupting mutations reduced ERK activation in tumors but not in 2D-adherent culture conditions further supporting the growing evidence that RAS signaling is context dependent [25] . In addition, the ability of wild-type K-RAS to heterodimerize with mutant K-RAS through this interface contributed to the sensitivity of lung tumor cells to MEK inhibitors and also provided a mechanistic explanation for the ability of the wild-type allele to inhibit the oncogenic version [25] . Thus, targeting this region with small molecules may provide a novel approach to inhibit K-RAS directly while also sensitizing K-RAS mutant cells to inhibitors of downstream signaling pathways.
Our results indicate that targeting the α4-α5 dimerization interface of K-RAS represents a valid approach to therapeutically inhibit K-RAS-driven tumors in vivo. Although NS1 in its current form is not a viable therapeutic given its Fig. 4 Targeting the α4-α5 interface decreases K-RAS-driven tumor development and progression. a HEC1A cells were injected into female athymic nude mice and then separated into three groups: 1) no DOX treatment (-DOX); 2) DOX treatment beginning 2 days after injection, + DOX (day 2); 3) DOX treatment upon tumor reaching 50-70 mm 3 , + DOX (day 9). n = 4 for each condition. Arrows denote tumors in mice upon sacrifice of animals. b Tumor kinetics of HEC1A cells. Tumor dimensions were recorded three times a week using a digital caliper. Data are presented as mean tumor volume ± SD. c Same as (a), except that the CFPAC-1 cells were injected into athymic nude mice. n = 6 for each condition (three males and three females). d Tumor kinetics of CFPAC-1 cells were measured as in (b). Data are presented as mean tumor volume ± SD large size and inability to penetrate cells, our work nevertheless demonstrates the "drug-like" activity of a genetically encoded NS1. These findings provide support to the goal of developing small-molecule mimetics of NS1 that directly bind to the α4-α5 interface. Such molecules may provide an opportunity to therapeutically inhibit RAS through disrupting RAS dimerization/nanoclustering, although such an approach may not provide selectivity in targeting mutationally activated vs wild-type RAS [16, 17] . Interestingly, we have observed that NS1 inhibits K-RAS mutant cells without affecting the proliferation of fibroblasts (HEK293 or NIH/3T3) grown in culture (Khan, I. and O'Bryan, J.P.; unpublished observations). This lack of "off-target" toxicity may stem from the selectivity of NS1 for H/K-RAS, allowing for the residual N-RAS function to drive proliferation in these NS1-expressing cells. Thus, it would be critical that such small molecules, like NS1, maintain isoform selectivity given that the loss of RAS in most adult tissues is not compatible with life [6] . Alternatively, the level of NS1 may be sufficient to inhibit oncogenic RAS without completely ablating wild-type RAS activity. In this instance, dosing of an NS1 mimetic would be critical in achieving the necessary therapeutic index.
Although it is unclear from our studies whether targeting α4-α5 dimerization interface will lead to tumor regression, it is nevertheless clear that inhibiting K-RAS dimerization reduces the overall tumor burden. Thus, combining dimerization inhibitors with inhibitors of RAS effector pathways such as MEK or mTOR may provide a more effective strategy for treating K-RAS mutant cancers.
Materials and methods
Cell culture
All cell lines were cultured as recommended by ATCC and were authenticated by short-tandem repeat profiling performed by the Research Resource Center at UIC. CFPAC-1, pancreatic cancer origin with endogenous K-RAS(G12V) mutation, was provided by Dr. Andrei Karginov; PANC-1 having K-RAS(G12D) mutation was obtained from Dr. Gregory Thatcher; HEC1A endometrial cancer line having K-RAS(G12D) mutation obtained from Dr. Todd Waldman; lung carcinoma lines H1792 with K-RAS(G12C) mutation and H1299 with N-RAS(Q61K) mutation were provided by Dr. Robert Winn; H1915 lung carcinoma cells with HRAS (Q61L) mutation was obtained from ATCC; and SK-N-AS neuroblastoma line with N-RAS(Q61K) mutation was obtained from Dr. Bernard Weisman. DOX-inducible NS1expressing cell lines were generated by the lentiviral infection of cells using the pTRIPz-CFP-NS1 construct as previously described [17] . Infected cells were selected in puromycin and resistant colonies pooled to generate polyclonal lines that were used for all subsequent analyses.
Immunoblotting
Cell lysates were prepared using PLC cell lysis buffer (50 mM HEPES (pH 7.5), 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EGTA, 1.5 mM magnesium chloride, 100 mM sodium fluoride supplemented with 1 mM NS1 expression was observed only in DOX-treated mice. Vinculin was used as a normalization control for ERK and pERK blots vanadate, 10 μg/ml leupeptin, and 10 μg/ml aprotinin). The following antibodies were used: α-ERK1/2, 1:2000 dilution (9102 L); α-phospho-ERK1/2, 1:2,000 dilution (9101 L); α-AKT, 1:4,000 dilution (9272 S); α-phospho-AKT (S473), 1:1,000 dilution (9271 S); and α-phospho-AKT (T308), 1:1,000 dilution (9275 S), all purchased from Cell Signaling Technology. Monoclonal α-FLAG-M2 antibody, 1:4,000 dilution (F3165-1MG); α-FLAG polyclonal antibody, 1:2,000 dilution (F7425-.2MG); and α-β-actin, 1:10000 dilution (A2066) were purchased from Sigma-Aldrich. α-Caspase-3, 1: 1,000 (sc-56053) and α-Vinculin, 1: 3,000 dilution (sc-73614) were purchased from Santa Cruz Biotechnology.
Cell viability assays
CFPAC-1, HEC1A, and H1299 cells (1,000 per well) were plated on 24-well plates in complete medium (Dulbecco's modified Eagle's medium with 10% fetal bovine serum plus 1 μg/ml puromycin and 2 μg/ml DOX to induce expression from the pTRIPz construct) for the indicated number of days. On the indicated day, the medium was removed and replaced with 100 μl of serum-free Dulbecco's modified Eagle's medium, and the cells were harvested after 30 min at 37°C. Viability was assayed using Cell Titer Glow (Promega). Luminescence was quantified on a Dynex 96-well microtiter plate luminometer according to the manufacturer's instructions. Results are presented as the average ± SD of two experiments each performed with triplicate wells.
NS1. Three weeks after plating, the cells were stained using MTT; 100 μl of 2 mg/ml solution of MTT was used for each well. Colony number and average colony size were quantified using ImageJ. Results represent the average colony number per well from three wells ± SD.
Xenograft tumor assays
Six-week-old male or female athymic nude mice from Charles River Laboratories (CRL) were housed in filtertopped cages and provided food and water ad libitum. Animal experiments were approved by the Institutional Animal Care and Use committees at all institutions. Power analysis performed prior to the initiation of animal experiments indicated that three mice per group would detect a 50% reduction in tumor volume (assume 1.8 cm 3 ± 0.9 cm 3 SD and 0.9 cm 3 ± 0.4 cm 3 SD ) with 95% confidence using statistical power calculators at https://www.dssresearch. com/KnowledgeCenter/toolkitcalculators/samplesizecalcula tors.aspx. Tumors were generated by s.c. injection into the right lower flank with 10 × 10 6 CFPAC-1 or H1299 cells; 5 × 10 6 HEC1A cells suspended in 60 μl of media and 60 μl matrigel (1:1 ratio). Twelve mice were used for each cell type. However, one mouse was excluded from the CFPAC-1 -DOX group and one mouse from the H1299 + DOX group due to the lack of tumor development likely stemming from poor injection of cells. DOX treatment was started at two different time points. 1) Two days following cell inoculation, mice were separated into DOX-treated (+ DOX, day 2) and control no-DOX group. DOX was provided as 2 mg/ml with water supplemented with sucrose. Tumor dimensions were recorded three times per week with a digital caliper and the tumor volume was estimated as V (mm³) = π/6(length × width²). When tumors reached 50-70 mm 3 mice were randomized and segregated into DOXtreated (+ DOX, day 9) and control no-DOX group. Results were analyzed for statistical significance using two-tailed Student's t test with GraphPad software.
